Screener
CapEx at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 5:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001493152-26-021764
| Line item | 2026 / For the Three Months Ended / March 31, | 2025 / For the Three Months Ended / March 31, |
|---|---|---|
| Operating lease liability | (35,229) | (15,827) |
| Net cash used in operating activities | (9,827,193) | (1,685,140) |
| Investing Activities: | ||
| Purchase of property and equipment | (32,486) | (67,713) |
| Proceeds from the sale of short-term investments | 3,000,000 | - |
| Purchase of short-term investments | (7,768,350) | - |
| Net cash used in investing activities | (4,800,836) | (67,713) |
| Financing Activities: |
Document
FAQ
- What is Immix Biopharma, Inc.'s capex?
- Immix Biopharma, Inc. (IMMX) reported capex of $32.49K in Q1 2026.
- How has Immix Biopharma, Inc.'s capex changed year-over-year?
- Immix Biopharma, Inc.'s capex decreased by 52.0% year-over-year, from $67.71K to $32.49K.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Immix Biopharma, Inc.'s capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude